JP2017522277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522277A5 JP2017522277A5 JP2016570862A JP2016570862A JP2017522277A5 JP 2017522277 A5 JP2017522277 A5 JP 2017522277A5 JP 2016570862 A JP2016570862 A JP 2016570862A JP 2016570862 A JP2016570862 A JP 2016570862A JP 2017522277 A5 JP2017522277 A5 JP 2017522277A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462009910P | 2014-06-10 | 2014-06-10 | |
| US62/009,910 | 2014-06-10 | ||
| PCT/US2015/034964 WO2015191630A1 (en) | 2014-06-10 | 2015-06-09 | Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522277A JP2017522277A (ja) | 2017-08-10 |
| JP2017522277A5 true JP2017522277A5 (enExample) | 2018-07-19 |
| JP6552061B2 JP6552061B2 (ja) | 2019-07-31 |
Family
ID=54834213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570862A Active JP6552061B2 (ja) | 2014-06-10 | 2015-06-09 | 代謝型グルタミン酸受容体の負のアロステリックモジュレーター（ｎａｍｓ）とその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US9969726B2 (enExample) |
| EP (1) | EP3154954B1 (enExample) |
| JP (1) | JP6552061B2 (enExample) |
| AU (1) | AU2015274781C1 (enExample) |
| CA (1) | CA2950952C (enExample) |
| WO (1) | WO2015191630A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10099993B2 (en) * | 2014-04-06 | 2018-10-16 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof |
| CA2950952C (en) | 2014-06-10 | 2023-01-10 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof |
| MX378998B (es) | 2015-06-03 | 2025-03-11 | Bristol Myers Squibb Co | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares. |
| CN108299303B (zh) * | 2018-02-09 | 2022-10-11 | 中山大学 | 一种四芳基吡唑类化合物的合成新方法 |
| CN108997325B (zh) * | 2018-07-06 | 2020-08-04 | 浙江工业大学 | 一种芳基联噻唑类化合物和应用 |
| AU2019310122A1 (en) * | 2018-07-27 | 2021-03-18 | With Great Power, Llc | Clinical methods and pharmaceutical compositions employing ampa receptor antagonists to treat glioblastoma and other cancers |
| US12366579B2 (en) * | 2019-03-21 | 2025-07-22 | University Of Virginia Patent Foundation | Sulfur-heterocycle exchange chemistry and uses thereof |
| CN110183382A (zh) * | 2019-06-06 | 2019-08-30 | 东北师范大学 | 新型三氟甲基吡唑类化合物合成方法 |
| AU2020316364A1 (en) * | 2019-07-22 | 2022-02-24 | Angion Biomedica Corp. | Ethynylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors |
| WO2021117759A1 (ja) | 2019-12-10 | 2021-06-17 | 塩野義製薬株式会社 | 含窒素芳香族複素環式基を有するヒストン脱アセチル化酵素阻害剤 |
| WO2022056447A1 (en) * | 2020-09-14 | 2022-03-17 | Genzyme Corporation | Carboxylic acid-containing compounds as modulators of bis-phosphoglycerate mutase for the treatment of sickle cell disease |
| CN112480073B (zh) * | 2020-12-02 | 2022-03-22 | 武汉药明康德新药开发有限公司 | 1-烷基-3,5-芳基取代的1,2,4三氮唑化合物的合成方法 |
| US20220265601A1 (en) * | 2021-02-10 | 2022-08-25 | David Alan Heldreth, JR. | Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses. |
| CN116041277B (zh) * | 2023-01-18 | 2024-11-01 | 中国药科大学 | 苯基和联苯基取代的五元杂环类化合物及其制备方法、药物组合物和应用 |
| US11970460B1 (en) | 2023-10-24 | 2024-04-30 | King Faisal University | 4-(4,5-bis(4-bromophenyl)-2-phenyl-1H-imidazol-1-yl)benzoic acid as an antimicrobial compound |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL357433A1 (en) | 1999-10-15 | 2004-07-26 | F.Hoffmann-La Roche Ag | Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| SI1224174T1 (en) | 1999-10-15 | 2003-12-31 | F. Hoffmann-La Roche Ag | Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| PL369598A1 (en) * | 2001-02-21 | 2005-05-02 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| NZ528345A (en) | 2001-04-12 | 2005-04-29 | F | Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mGluR2 antagonists I |
| EP1379511B1 (en) * | 2001-04-12 | 2005-07-20 | F. Hoffmann-La Roche Ag | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II |
| WO2002096905A1 (en) * | 2001-06-01 | 2002-12-05 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinases |
| US6949542B2 (en) | 2002-02-06 | 2005-09-27 | Hoffman-La Roche Inc. | Dihydro-benzo[b][1,4]diazepin-2-one derivatives |
| WO2003077918A1 (en) * | 2002-03-12 | 2003-09-25 | Merck & Co., Inc. | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| EP1572693A1 (en) * | 2002-12-20 | 2005-09-14 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
| EP1613615A2 (en) * | 2003-04-03 | 2006-01-11 | Merck & Co., Inc. | 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5 |
| US20090018150A1 (en) * | 2003-07-24 | 2009-01-15 | Asterand Uk Limited | 5-Ht2b Receptor Antagonists |
| EP1753428A4 (en) * | 2004-05-14 | 2010-09-15 | Abbott Lab | INHIBITORS OF KINASES AS THERAPEUTIC AGENTS |
| AU2006261841B8 (en) * | 2005-06-27 | 2012-12-06 | Exelixis Patent Company Llc | Pyrazole based LXR modulators |
| AU2007229552C1 (en) | 2006-03-29 | 2013-06-13 | F. Hoffmann-La Roche Ag | Pyridine and pyrimidine derivatives as mGluR2 antagonists |
| US8012986B2 (en) * | 2007-04-02 | 2011-09-06 | Hoffmann-La Roche Inc. | Pyridine and pyrimidine derivatives as MGLUR2 antagonists |
| EP2145873A1 (fr) * | 2008-06-17 | 2010-01-20 | Commissariat A L'energie Atomique | Nouveaux composés ayant une activité protectrice vis-à-vis de l'action de toxines et de virus au mode d'action intracellulaire |
| MX2012006778A (es) * | 2009-12-14 | 2012-07-23 | Msd Oss Bv | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno. |
| US8748632B2 (en) * | 2010-03-19 | 2014-06-10 | Sanford-Burnham Medical Research Institute | Positive allosteric modulators of group II mGluRs |
| EP2751095B1 (en) * | 2011-08-29 | 2021-10-27 | Sanford-Burnham Medical Research Institute | Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof |
| GB201321743D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| CA2950952C (en) | 2014-06-10 | 2023-01-10 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof |
-
2015
- 2015-06-09 CA CA2950952A patent/CA2950952C/en active Active
- 2015-06-09 AU AU2015274781A patent/AU2015274781C1/en active Active
- 2015-06-09 WO PCT/US2015/034964 patent/WO2015191630A1/en not_active Ceased
- 2015-06-09 US US15/315,363 patent/US9969726B2/en active Active
- 2015-06-09 JP JP2016570862A patent/JP6552061B2/ja active Active
- 2015-06-09 EP EP15806027.7A patent/EP3154954B1/en active Active
-
2018
- 2018-04-11 US US15/950,683 patent/US10597367B2/en active Active
-
2020
- 2020-03-12 US US16/817,209 patent/US11447453B2/en active Active
-
2022
- 2022-08-08 US US17/883,255 patent/US20230113588A1/en active Pending